Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis-Reference-Cited by-同舟云学术

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

Published:2020-02-20 Issue:8 Volume:382 Page:706-716
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Ständer Sonja¹,Yosipovitch Gil¹,Legat Franz J.¹,Lacour Jean-Philippe¹,Paul Carle¹,Narbutt Joanna¹,Bieber Thomas¹,Misery Laurent¹,Wollenberg Andreas¹,Reich Adam¹,Ahmad Faiz¹,Piketty Christophe¹

Affiliation:

1. From the Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster (S.S.), the Department of Dermatology and Allergy, Christine Kühne Center for Allergy Research and Education, University Hospital, Bonn (T.B.), and the Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich (A.W.) — all in Germany; the Itch Center, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Hospital, Miami (G.Y.); the...

Funder

Nestle Skin Health

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1908316

Cited by 211 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abrocitinib for prurigo nodularis: Clinical efficacy and safety profile;Journal of the European Academy of Dermatology and Venereology;2024-09-12

2. Prurigo: review of its pathogenesis, diagnosis, and treatment;Anais Brasileiros de Dermatologia;2024-09

3. The role of nemolizumab in the treatment of atopic dermatitis for the adult population;Immunotherapy;2024-08-09

4. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration;Allergy;2024-08-04

5. 672 - Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies;British Journal of Dermatology;2024-08